Endocyte Announces Clinical Updates for EC1456 and EC1169
ENDOCYTE (ECYT)
Last endocyte earnings: 11/7 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.endocyte.com/investor-relations
Company Research
Source: GlobeNewswire
- Company Continuing EC1169 Program in Taxane-Exposed Patients, but Ending Clinical Development of EC1456 and of EC1169 in Taxane-Naïve Patients - - Refocusing Efforts on Chimeric Antigen Receptor T-cell (CAR T-cell) and Dual-Targeted DNA Crosslinker Drug EC2629 Programs - - Restructuring to Reduce Workforce by Approximately 40%; Will Maintain Core Competencies and Preserve Capital for Highest Priority Programs - - Conference Call Today at 8:30 a.m. EDT - WEST LAFAYETTE, Ind., June 02, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced updates on clinical development for EC1456, its folate receptor-targeted tubulysin cancer therapy, and EC1169, its prostate-specific membrane antigen targeted (PSMA-targeted) tubulysin prostate cancer therapy. Endocyte will narrow the EC1169 development program to focus only on the cohort of taxane-ex
Show less
Read more
Impact Snapshot
Event Time:
ECYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ECYT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ECYT alerts
High impacting ENDOCYTE news events
Weekly update
A roundup of the hottest topics